drugset
drugset / Trial / NCT04076293

Single Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15912(Sonefpeglutide) in Healthy Korean Subjects

NCT04076293 ↗

Phase 1 Completed 40 enrolled Hanmi Pharmaceutical Company Limited
RandomizedSequentialQuadruple-blindTreatment

Summary

A First-in-Human, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15912 in Healthy Korean Subjects

Timeline

Start
2019-10-08
Primary completion
2020-11-10
Completion
2021-05-03

Drugs

EvaluationDrugModalityDoseRoute
Subject HM15912 Unknown — —

Indications

No indication recorded.